down arrow

Forte Biosciences, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US34962G1094
USD
20.56
1.47 (7.7%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

17.8220.56

52 Week

4.9028.68
Valuation
Technical
Day's Volume

CASH

47.88 k

Shareholding (Mar 2025)

FII

10.35%

Held by 8 FIIs

DII

69.18%

Held by 12 DIIs

Promoter

9.28%

How big is Forte Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Forte Biosciences, Inc. has a market capitalization of 81.50 million and reported net sales of 0.00 million with a net profit of -43.72 million over the last four quarters. The balance sheet shows shareholder's funds of 52.48 million and total assets of 61.56 million.

As of Jun 18, Forte Biosciences, Inc. has a market capitalization of 81.50 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -43.72 million during the same period.<BR><BR>As of Dec 24, the balance sheet indicates shareholder's funds of 52.48 million and total assets of 61.56 million.

Read More

What does Forte Biosciences, Inc. do?

22-Jun-2025

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company developing live biotherapeutics for inflammatory skin diseases, particularly pediatric atopic dermatitis. It operates in the micro-cap market with a market cap of $81.50 million and reported a net profit loss of $16 million as of March 2025.

Overview: <BR>Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a live biotherapeutic for the treatment of inflammatory skin diseases, particularly for pediatric atopic dermatitis patients, and operates within the Pharmaceuticals & Biotechnology industry in the micro-cap market.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -16 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 81.50 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.19 <BR>Return on Equity: -113.76% <BR>Price to Book: 2.12<BR><BR>Contact Details: <BR>Address: 1124 W Carson Street, Mrl Building 3-320, TORRANCE CA: 90502 <BR>Tel: ['1 310 6186994', '1 415 5159763'] <BR>Fax: 1 302 6555049 <BR>Website: https://tocagen.com

Read More

Who are in the management team of Forte Biosciences, Inc.?

22-Jun-2025

As of March 2022, the management team of Forte Biosciences, Inc. is led by Dr. Paul Wagner as Chairman, President, and CEO, with the board of directors including Mr. Thomas Darcy, Dr. Lawrence Eichenfield, Mr. Steven Kornfeld, Dr. Patricia Walker, and Mr. Donald Williams.

As of March 2022, the management team of Forte Biosciences, Inc. includes Dr. Paul Wagner, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the board of directors consists of Mr. Thomas Darcy, Dr. Lawrence Eichenfield, Mr. Steven Kornfeld, Dr. Patricia Walker, and Mr. Donald Williams, all of whom hold the designation of Director.

Read More

Is Forte Biosciences, Inc. overvalued or undervalued?

25-Jun-2025

Forte Biosciences, Inc. is currently considered overvalued due to negative financial metrics, including a Price to Book Value of 1.94 and a negative ROE of -113.76%, alongside poor performance compared to peers and a year-to-date return of -43.81%.

As of 12 November 2019, the valuation grade for Forte Biosciences, Inc. moved from risky to does not qualify, indicating a significant downgrade in its financial standing. The company is currently considered overvalued based on its financial ratios and peer comparisons. Key ratios include a Price to Book Value of 1.94, a negative ROE of -113.76%, and an EV to EBITDA ratio of -0.64, which reflects a lack of profitability.<BR><BR>In comparison to its peers, Forte Biosciences shows a stark contrast; for instance, Pieris Pharmaceuticals, Inc. has a P/E ratio of -13.97 and an EV to EBITDA of -9.60, while OncoCyte Corp. is rated risky with an EV to EBITDA of -2.86. The company's recent performance has also been poor, with a year-to-date return of -43.81%, significantly underperforming the S&P 500, which has returned 2.44% in the same period. Overall, the combination of negative financial metrics and poor peer performance suggests that Forte Biosciences is currently overvalued.

Read More

Is Forte Biosciences, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Forte Biosciences, Inc. is in a mildly bearish trend despite a strong short-term performance of 26.29%, with bearish indicators outweighing a bullish MACD.

As of 8 September 2025, the technical trend for Forte Biosciences, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly KST and OBV are also mildly bearish. Although the MACD is bullish on a weekly basis and mildly bullish on a monthly basis, the overall sentiment is tempered by the bearish indicators. The stock has shown strong short-term performance with a 26.29% return over the past week, significantly outperforming the S&P 500's 1.05%, but it remains down 41.83% year-to-date compared to the S&P's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 138 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.08

stock-summary
Return on Equity

-43.05%

stock-summary
Price to Book

1.40

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-11 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
85.73%
0%
85.73%
6 Months
115.29%
0%
115.29%
1 Year
-14.33%
0%
-14.33%
2 Years
65.14%
0%
65.14%
3 Years
1976.77%
0%
1976.77%
4 Years
-63.29%
0%
-63.29%
5 Years
-97.81%
0%
-97.81%

Forte Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Forte Biosciences, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Forte Biosciences, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly KST and OBV are also mildly bearish. Although the MACD is bullish on a weekly basis and mildly bullish on a monthly basis, the overall sentiment is tempered by the bearish indicators. The stock has shown strong short-term performance with a 26.29% return over the past week, significantly outperforming the S&P 500's 1.05%, but it remains down 41.83% year-to-date compared to the S&P's 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-0.40%
EBIT Growth (5y)
-2.39%
EBIT to Interest (avg)
-26.83
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.19
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
84.12%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.94
EV to EBIT
-0.64
EV to EBITDA
-0.64
EV to Capital Employed
-3.86
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-113.76%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (11.19%)

Foreign Institutions

Held by 8 Foreign Institutions (10.35%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 10.40% vs -40.45% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.60",
          "val2": "-12.80",
          "chgp": "9.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.20",
          "val2": "-12.50",
          "chgp": "10.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -12.70% vs -126.62% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-36.60",
          "val2": "-32.50",
          "chgp": "-12.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-35.50",
          "val2": "-31.50",
          "chgp": "-12.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-11.60
-12.80
9.38%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-11.20
-12.50
10.40%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 10.40% vs -40.45% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-36.60
-32.50
-12.62%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-35.50
-31.50
-12.70%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -12.70% vs -126.62% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Forte Biosciences, Inc. stock-summary
stock-summary
Forte Biosciences, Inc.
Pharmaceuticals & Biotechnology
Forte Biosciences, Inc., formerly Tocagen Inc., is a clinical-stage biopharmaceutical company. The Company is focused on clinical program and developing a live biotherapeutic for the treatment of inflammatory skin diseases, particularly for pediatric atopic dermatitis patients. It provides FB-401, which is a live biotherapeutic for the treatment of inflammatory skin diseases. FB-401 has completed Phase I/II a testing in adult and pediatric patients with atopic dermatitis.
Company Coordinates stock-summary
Company Details
1124 W Carson Street, Mrl Building 3-320 , TORRANCE CA : 90502
stock-summary
Tel: 1 310 61869941 415 5159763
stock-summary
https://tocagen.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."